ERBB2 and esophageal squamous cell carcinoma: However, it has been shown that esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are inherently resistant to systemic therapy due to histology, molecular and etiological heterogeneity, with limited responses seen after first‐line therapy.3 The application of targeted drugs is very limited in esophageal cancer,and is only administered in EAC targeting HER2 or vascular endothelial growth factor4, 5, 6,and there is no current evidence showing that targeted therapy has an obvious benefit in ESCC.